Small-molecule HDAC inhibitors are a well-established class of epigenetic drugs designed to inhibit the catalytic activity of HDACs, leading to hyperacetylation of histones and non-histone proteins, chromatin decondensation, and reactivation of tumor suppressor genes [67, 68]. The gene discussed is HDAC9; the disease is neoplasm.